Currently out of the existing stock ratings of Liana Moussatos, 179 are a BUY (89.95%), 19 are a HOLD (9.55%), 1 are a SELL (0.5%).

Liana Moussatos

Work Performance Price Targets & Ratings Chart

Analyst Liana Moussatos, currently employed at WEDBUSH, carries an average stock price target met ratio of 40.92% that have a potential upside of 45.43% achieved within 294 days.

Liana Moussatos’s has documented 393 price targets and ratings displayed on 27 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CLSD, Clearside Biomedical at 13-Mar-2024.

Wall Street Analyst Liana Moussatos

Analyst best performing recommendations are on GRAY (GRAYBUG VISION).
The best stock recommendation documented was for GRAY (GRAYBUG VISION) at 3/9/2021. The price target of $8 was fulfilled within 2 days with a profit of $0.8 (11.11%) receiving and performance score of 55.56.

Average potential price target upside

of $88.8 (65.59%) on UTHR (UNITED THERAPEUTICS).
of $37.9 (101.35%) on PCRX (PACIRA PHARMACEUTICALS).
of $33.19 (58.63%) on BPMC (BLUEPRINT MEDICINES CORP).

AIMT Aimmune Therapeutics ALBO Albireo Pharma AQST Aquestive Therapeutics ASND Ascendis Pharma AS BMRN Biomarin Pharmaceutical BPMC Blueprint Medicines Corp CATB Catabasis Pharmaceuticals CLSD Clearside Biomedical ICPT Intercept Pharmaceuticals LQDA Liquidia Technologies LXRX Lexicon Pharmaceuticals OMER Omeros PCRX Pacira Pharmaceuticals RGLS Regulus Therapeutics RLYP Relypsa SGMO Sangamo Therapeutics UTHR United Therapeutics VRNA Verona Pharma PLC ADR XOMA XOMA Corp AXLA Axcella Health GRAY Graybug Vision IMUX Immunic MGEN Viridian Therapeutics EIGR Eiger Biopharmaceuticals OBSV ObsEva SA ATXS Astria Therapeutics GBT Global Blood Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Derek Archila (WELLS FARGO)